This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PRTK Paratek Pharmaceuticals (PRTK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Paratek Pharmaceuticals Stock (NASDAQ:PRTK) 30 days 90 days 365 days Advanced Chart Get PRTK alerts:Sign Up Key Stats Today's Range$2.23▼$2.2350-Day Range$2.17▼$2.2352-Week Range$1.29▼$3.65VolumeN/AAverage Volume724,253 shsMarket Capitalization$127.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts. Read More Receive PRTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRTK Stock News HeadlinesOptinose CEO and other top executives exit after company's acquisition by ParatekMay 23, 2025 | bizjournals.comParatek expands commercial portfolio with OptinoseMay 22, 2025 | msn.comTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real wealth for early adopters In 1933, Executive Order 6102 forced everyday Americans to hand over their gold at a fixed rate. Everyday citizens lost a sizable amount of their hard earned wealth at the stroke of FDR's pen.September 16 at 2:00 AM | American Hartford Gold (Ad)OptiNose Shareholders Approve Merger with ParatekMay 18, 2025 | investing.comParatek Pharmaceuticals to Present Clinical Data on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International ConferenceMay 16, 2025 | globenewswire.comHow a Bucks County firm's multiyear pursuit of a partner led to a potential $330M dealApril 11, 2025 | bizjournals.comParatek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025April 10, 2025 | globenewswire.comParatek Pharmaceuticals to acquire Optinose in $330M transactionMarch 21, 2025 | markets.businessinsider.comSee More Headlines PRTK Stock Analysis - Frequently Asked Questions How were Paratek Pharmaceuticals' earnings last quarter? Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) released its earnings results on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.08. The specialty pharmaceutical company had revenue of $24.45 million for the quarter, compared to analyst estimates of $22.98 million. What other stocks do shareholders of Paratek Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Paratek Pharmaceuticals investors own include Energy Transfer (ET), Sorrento Therapeutics (SRNE), Micron Technology (MU), Verastem (VSTM), Citius Pharmaceuticals (CTXR), SCYNEXIS (SCYX) and Aurinia Pharmaceuticals (AUPH). Company Calendar Last Earnings11/08/2021Today9/16/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PRTK Previous SymbolNASDAQ:TSPT CIK1178711 Webwww.paratekpharma.com Phone(617) 807-6600Fax617-275-0039Employees268Year Founded1996Profitability EPS (Trailing Twelve Months)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.57 million Net Margins-35.44% Pretax Margin-35.35% Return on EquityN/A Return on Assets-40.05% Debt Debt-to-Equity RatioN/A Current Ratio0.52 Quick Ratio0.46 Sales & Book Value Annual Sales$160.27 million Price / Sales0.80 Cash FlowN/A Price / Cash FlowN/A Book Value($3.08) per share Price / Book-0.72Miscellaneous Outstanding Shares57,320,000Free Float52,736,000Market Cap$127.82 million OptionableOptionable Beta1.70 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:PRTK) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Paratek Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Paratek Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.